Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EchoIQ Limited ( (AU:EIQ) ) has provided an announcement.
Echo IQ Limited has successfully completed the clinical validation of its heart failure detection software, EchoSolv HF, in collaboration with the Mayo Clinic Platform. The study, which analyzed 17,000 echocardiograms, demonstrated exceptional accuracy, with a sensitivity of 99.5% and specificity of 91.0%. This milestone paves the way for the company’s FDA 510(k) submission, potentially unlocking a significant market opportunity in the US, where heart failure is a major health issue. Upon FDA clearance, Echo IQ plans to leverage its existing US market presence to promote EchoSolv HF, aiming to improve the early detection and treatment of heart failure, which is currently underdiagnosed and undertreated.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
More about EchoIQ Limited
Echo IQ Limited is a Sydney-based company that utilizes AI-driven technology and proprietary software to enhance decision-making in cardiology.
Average Trading Volume: 1,576,178
Technical Sentiment Signal: Buy
Current Market Cap: A$149.6M
For a thorough assessment of EIQ stock, go to TipRanks’ Stock Analysis page.